BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lin C, Tseng T, Kao J. What can we learn from hepatitis B virus clinical cohorts? Liver Int 2015;35:91-9. [DOI: 10.1111/liv.12716] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Ducancelle A, Pivert A, Bertrais S, Boursier J, Balan V, Veillon P, le Guillou-Guillemette H, Thibault V, Castelain S, Roquebert B, Coste-Burel M, Mackiewicz V, Schvoerer E, Larrat S, Maylin S, Alain S, Loustaud-Ratti V, Gordien E, Gozlan J, Brodard V, Chevaliez S, Calès P, Lunel-Fabiani F. Different precore/core mutations of hepatitis B interact with, limit, or favor liver fibrosis severity. J Gastroenterol Hepatol 2016;31:1750-6. [PMID: 26992056 DOI: 10.1111/jgh.13338] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
2 Mallet V, Hamed K, Schwarzinger M. Prognosis of patients with chronic hepatitis B in France (2008–2013): A nationwide, observational and hospital-based study. Journal of Hepatology 2017;66:514-20. [DOI: 10.1016/j.jhep.2016.10.031] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 4.2] [Reference Citation Analysis]
3 Magalhães-Costa P, Lebre L, Peixe P, Santos S, Chagas C. Hepatocellular Carcinoma in Chronic Hepatitis B Patients on Third Generation Nucleos(t)ides Analogs: Risk Factors and Performance of a Risk Score. GE Port J Gastroenterol 2016;23:233-42. [PMID: 28868468 DOI: 10.1016/j.jpge.2016.02.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
4 Yim SY, Kim JH. The epidemiology of hepatitis B virus infection in Korea. Korean J Intern Med 2019;34:945-53. [PMID: 30919608 DOI: 10.3904/kjim.2019.007] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
5 Nishikawa H, Hasegawa K, Ishii A, Takata R, Enomoto H, Yoh K, Kishino K, Shimono Y, Iwata Y, Nakano C, Nishimura T, Aizawa N, Sakai Y, Ikeda N, Takashima T, Iijima H, Nishiguchi S. A proposed predictive model for advanced fibrosis in patients with chronic hepatitis B and its validation. Medicine (Baltimore) 2016;95:e4679. [PMID: 27583895 DOI: 10.1097/MD.0000000000004679] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
6 Ishii A, Nishikawa H, Enomoto H, Iwata Y, Kishino K, Shimono Y, Hasegawa K, Nakano C, Takata R, Nishimura T, Yoh K, Aizawa N, Sakai Y, Ikeda N, Takashima T, Iijima H, Nishiguchi S. Clinical implications of serum Wisteria floribunda agglutinin-positive Mac-2-binding protein in treatment-naïve chronic hepatitis B. Hepatol Res 2017;47:204-15. [PMID: 26990490 DOI: 10.1111/hepr.12703] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
7 Lin C, Kao J. Perspectives and control of hepatitis B virus infection in Taiwan. Journal of the Formosan Medical Association 2015;114:901-9. [DOI: 10.1016/j.jfma.2015.06.003] [Cited by in Crossref: 49] [Cited by in F6Publishing: 48] [Article Influence: 7.0] [Reference Citation Analysis]
8 Yang H, Kao J. Revisiting the Natural History of Chronic HBV Infection. Curr Hepatology Rep 2016;15:141-9. [DOI: 10.1007/s11901-016-0304-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
9 Hoang JK, Yang HI, Le A, Nguyen NH, Lin D, Vu VD, Chaung K, Nguyen V, Trinh HN, Li J, Zhang JQ, Chen CJ, Nguyen MH. Lower liver cancer risk with antiviral therapy in chronic hepatitis B patients with normal to minimally elevated ALT and no cirrhosis. Medicine (Baltimore) 2016;95:e4433. [PMID: 27495067 DOI: 10.1097/MD.0000000000004433] [Cited by in Crossref: 20] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]